Noam Shabani PA-C speaks to ecancer about what physician assistants need to know about PARP inhibitors in metastatic prostate cancer.

He explains which patients are suitable for treating with PARP inhibitors and how they compare to other treatment options.

Noam concludes by saying that research is still underway that can help inform what role PARP inhibitors play in the treatment of advanced prostate cancer.

This programme has been supported by an unrestricted educational grant from Pfizer.